Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress opposes FDA CBE rule

This article was originally published in The Tan Sheet

Executive Summary

In a Jan. 23 letter to FDA, eight leading members of the House and Senate criticize the agency's proposed rule to limit when a manufacturer can revise product labeling without prior FDA approval. "We are concerned that the intent of this proposal is to protect companies in the pharmaceutical and device industry from being held liable for marketing products they know are unsafe," the letter states. The signatories, who include Rep. Henry Waxman, D-Calif., and Sen. Edward Kennedy, D-Mass, request FDA to provide data on labeling revisions. The proposed rule reiterates the agency's position that FDA-approved labeling preempts state tort claims. The issue of preemption is being addressed by the U.S. Supreme Court in several cases, including Wyeth v. Levine...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts